Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer

(2010) Mark Garzotto et al.   CANCER

Targeted therapeutic approaches for hormone-refractory prostate cancer

(2010) Flora Stavridi et al.   CANCER TREATMENT REVIEWS

Targeted therapy for advanced prostate cancer: Looking through new lenses

(2010) P. Vogiatzi et al.   DRUG NEWS & PERSPECTIVES

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Is focal therapy the future for prostate cancer?

(2010) Hashim U Ahmed et al.   Future Oncology

Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells

(2009) Koji Azuma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Silencing prostate cancer

(2009) Ivanka Toudjarska et al.   NATURE BIOTECHNOLOGY

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

(2009) J Mullenders et al.   ONCOGENE

Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs

(2009) Catherine Sánchez et al.   PROSTATE

The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer

(2009) Hector R. Contreras et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins

(2008) Nicola Antonio Colabufo et al.   EUROPEAN JOURNAL OF PHARMACOLOGY